Generate Biomedicines (GENB) investor relations material

Executive summary

• GB-0895 advanced in two Phase 3 severe-asthma trials; Phase 1b COPD data showed single-dose biomarker reductions sustained for at least six months.

• GB-4362 advanced dose escalation, and the first patient was dosed in the GB-5267 Phase 1 trial; Zealand and Anthropic collaborations expanded metabolic-disease and AI-guided CAR T research.

• Collaboration revenue declined as Novartis and Amgen obligations neared completion, while GB-0895 Phase 3 and CMC spending lifted R&D costs.

• Cash, cash equivalents and marketable securities of $404.2M, plus Zealand’s $30.0M October upfront payment, are expected to fund the current operating plan into H1 2028.

Financial highlights

• Q3 2026 revenue was $4.2M vs. $9.6M YoY; operating expenses were $95.7M vs. $72.4M, and operating loss was $91.5M vs. $62.8M.

• Q3 R&D expense was $82.3M vs. $62.2M and G&A was $13.5M vs. $10.3M; higher R&D primarily reflected GB-0895 Phase 3 investment.

• Q3 net loss was $87.7M vs. $60.0M; net loss per share was $0.68 vs. $1.97, with weighted-average shares of 128.5M vs. 33.0M.

• 9M 2026 revenue was $17.8M vs. $28.6M; net loss was $216.6M vs. $161.1M, and operating loss was $227.2M vs. $171.1M.

• 9M R&D expense rose to $204.4M from $168.7M and G&A to $40.6M from $31.0M.

Outlook and guidance

• Cash resources and Zealand’s $30.0M upfront payment are expected to support the current operating plan into H1 2028; additional capital is expected for long-term operations.

• R&D spending and operating losses are expected to increase as clinical programs advance; no product-sales revenue is expected for several years, if ever.

• Novartis and Amgen performance obligations are expected to be completed in 2027; remaining transaction prices were $7.0M and $1.0M, respectively, at September 30, 2026.